Unknown

Dataset Information

0

Blockade of muscarinic acetylcholine receptors facilitates motivated behaviour and rescues a model of antipsychotic-induced amotivation.


ABSTRACT: Disruptions to motivated behaviour are a highly prevalent and severe symptom in a number of neuropsychiatric and neurodegenerative disorders. Current treatment options for these disorders have little or no effect upon motivational impairments. We assessed the contribution of muscarinic acetylcholine receptors to motivated behaviour in mice, as a novel pharmacological target for motivational impairments. Touchscreen progressive ratio (PR) performance was facilitated by the nonselective muscarinic receptor antagonist scopolamine as well as the more subtype-selective antagonists biperiden (M1) and tropicamide (M4). However, scopolamine and tropicamide also produced increases in non-specific activity levels, whereas biperiden did not. A series of control tests suggests the effects of the mAChR antagonists were sensitive to changes in reward value and not driven by changes in satiety, motor fatigue, appetite or perseveration. Subsequently, a sub-effective dose of biperiden was able to facilitate the effects of amphetamine upon PR performance, suggesting an ability to enhance dopaminergic function. Both biperiden and scopolamine were also able to reverse a haloperidol-induced deficit in PR performance, however only biperiden was able to rescue the deficit in effort-related choice (ERC) performance. Taken together, these data suggest that the M1 mAChR may be a novel target for the pharmacological enhancement of effort exertion and consequent rescue of motivational impairments. Conversely, M4 receptors may inadvertently modulate effort exertion through regulation of general locomotor activity levels.

SUBMITTER: Hailwood JM 

PROVIDER: S-EPMC6397643 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Blockade of muscarinic acetylcholine receptors facilitates motivated behaviour and rescues a model of antipsychotic-induced amotivation.

Hailwood Jonathan M JM   Heath Christopher J CJ   Phillips Benjamin U BU   Robbins Trevor W TW   Saksida Lisa M LM   Bussey Timothy J TJ  

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20181127 6


Disruptions to motivated behaviour are a highly prevalent and severe symptom in a number of neuropsychiatric and neurodegenerative disorders. Current treatment options for these disorders have little or no effect upon motivational impairments. We assessed the contribution of muscarinic acetylcholine receptors to motivated behaviour in mice, as a novel pharmacological target for motivational impairments. Touchscreen progressive ratio (PR) performance was facilitated by the nonselective muscarinic  ...[more]

Similar Datasets

| S-EPMC7425847 | biostudies-literature
| S-EPMC1574958 | biostudies-literature
| S-EPMC8229778 | biostudies-literature
| S-EPMC9757584 | biostudies-literature
| S-EPMC9081114 | biostudies-literature
| S-EPMC4049973 | biostudies-literature
| S-EPMC4294565 | biostudies-literature
| S-EPMC4915387 | biostudies-literature
| S-EPMC2666819 | biostudies-literature
| S-EPMC4399838 | biostudies-literature